Investment
Features
FeesSafety
Academy
More
Pluang+

Bunzl PLC beats earnings estimates, raises margin forecast, and launches £500M share buyback.

Company Fundamentals
01 Sep 2026
Danny Green
View Source
Bullish
pluang ai news

Bunzl PLC reported stronger-than-expected financial results with an EPS of $0.60, surpassing the $0.56 consensus. Revenue reached $8.04 billion, driven by a 3.2% underlying growth, especially in North America. The operating margin improved to 7.3%, prompting an upgraded full-year margin forecast of 7.6%. The company also announced a £500 million share buyback program, signaling confidence in its future prospects and aiming to enhance shareholder value.

More News

Palo Alto Networks expects strong Q3 earnings and revenue growth amid positive cybersecurity trends.

Palo Alto Networks expects strong Q3 earnings and revenue growth amid positive cybersecurity trends.

Palo Alto Networks is set to report strong earnings per share (EPS) of $0.98 and revenue of $3.35 billion for the upcoming quarter, reflecting significant growth from last year. Investor optimism is driven by robust cybersecurity sector trends and a ...

Company Fundamentals
Bullish
1 hour ago
Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
2 hours ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
3 hours ago
SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App